JAAD Lines Up a November 2026 Paper on Biologic Requests and Social Media

JAAD Lines Up a November 2026 Paper on Biologic Requests and Social Media

Six authors anchored by Jane M. Grant-Kels frame the patient-driven prescribing collision in next month's print issue.

The November 2026 issue of the Journal of the American Academy of Dermatology — Volume 95, Issue 5 — will carry a paper aimed at one of the more uncomfortable friction points in modern outpatient practice: the gap between what patients ask for after watching a dermatologist influencer online, and what payers will approve after a peer-to-peer review.

The paper's title names the collision directly: "Biologic requests in the era of social media and administrative medicine." Six authors are listed: Anshu Jonnalagadda, Weston P. Lowry, Ana B.W. Greenberg, Amar D. Desai, Albert E. Zhou, and Jane M. Grant-Kels.

What does the title tell us?

Three nouns, one sentence. Biologics. Social media. Administrative medicine. That triad maps the typical Tuesday morning in a U.S. dermatology clinic: a patient walks in naming a specific biologic, citing a creator or sponsored post they saw that week. The clinician may agree the drug is reasonable. The back office then opens the prior-auth queue.

JAAD hasn't released the article's full text ahead of the November issue, so the study design, findings, and recommendations aren't yet quotable. The title alone, though, marks the topic as one the journal's editors cleared for peer-reviewed treatment.

Why does the timing matter?

Two trends have run in opposite directions. The roster of FDA-approved biologics in dermatology has expanded across the past five years, widening what a patient can plausibly request. Payers, in parallel, have layered on step therapy, reauthorization cycles, and accumulator programs. Social media has compressed the lag between a drug's approval and a patient's ability to name it in the exam room.

The category of visit that results — the patient-driven biologic request — barely existed a decade ago.

What should readers look for in the November issue?

Derm Field readers should check the issue for several reportable elements once it lands:

• Study design — survey, payer-claims analysis, position piece, or some combination.
• Any quantification of administrative time per biologic request, even as a secondary finding.
• Documentation language for medical-necessity letters that survives payer review.
• Any direct editorial line on off-label requests driven by social-media content for agents approved in adjacent indications.

What does this change for clinicians?

Practically, a peer-reviewed framing matters. A JAAD-cited argument that a patient-requested biologic is clinically reasonable carries more force in a peer-to-peer review than the same argument made by an anxious caller holding a phone on speaker.

For practice administrators, even a viewpoint piece from this author group can sharpen the templates their billing teams already use.

For payers — and this is the longer arc — sustained editorial pressure in dermatology's flagship journal is one of the levers the specialty uses to push back on step-therapy rules that lag behind guideline updates.

The bottom line

A November 2026 JAAD paper will put a citation behind a problem dermatologists describe anecdotally every clinic day. The full recommendations wait for the print issue. Until then, the title alone is enough to tell the specialty: this friction has earned its peer-reviewed moment.